PharmaTimes October 9, 2024
New investment to advance gene therapies for kidney diseases
Purespring Therapeutics has raised £80m in an oversubscribed Series B financing round. Syncona Ltd, a leading life science investor, committed £19.9m as part of a syndicate led by Sofinnova, alongside Gilde Healthcare, Forbion and British Patient Capital.
The funds will be used to advance Purespring’s pipeline of gene therapies for kidney diseases, with clinical trials expected to begin in 2026.
Michael Kyriakides, Investment Partner at Syncona and Board Director of Purespring, expressed his enthusiasm: “Syncona founded Purespring with the vision of creating the world’s leading kidney gene therapy company and we have been impressed with its progress.”
He added: “Today’s financing and the strong syndicate of investors that the company has...
Today's Sponsors
Today's Sponsor